ADC Therapeutics SA
NYSE:ADCT
P/OCF
Price to OCF
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
Market Cap | P/OCF | ||||
---|---|---|---|---|---|
CH |
ADC Therapeutics SA
NYSE:ADCT
|
409.3m USD | -3 | ||
US |
Abbvie Inc
NYSE:ABBV
|
293.2B USD | 12.8 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
141.2B USD | 16.7 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
101.4B USD | 28.7 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
98.2B USD | 21.4 | ||
AU |
CSL Ltd
ASX:CSL
|
131.7B AUD | 31.5 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
82.3B USD | 10.3 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -79.9 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
39.2B USD | -12.6 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
27.6B USD | 17.8 | ||
IE |
Horizon Therapeutics PLC
NASDAQ:HZNP
|
26.6B USD | 25.6 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.